Growth factor modulation of hepatic inflammation: a novel approach to the management of total parenteral nutrition–associated liver disease

The effect of hepatocyte growth factor on gene transcription during intestinal adaptation

“…We have previously studied the effect of HGF using different models from the one described in this study including an animal model of inflammatory bowel disease [25], a small bowel ischemia-reperfusion model [26,27], and a total parenteral nutrition-induced liver injury model [28,29]. Several results were consistent across all of our studies.…”

Development of a Reproducible Model of Parenteral Nutrition-Associated Liver Disease in Rats

“…Previous studies from our laboratory have had similar results even when using a more established model of PNALD with injections of the cholestatic agent α-naphtylisocyocyanate. 10 Our histological studies did not reveal evidence of acute inflammation and, thus, you would not expect to have elevations in liver enzymes. In the setting of chronic inflammation, which we have demonstrated in the aluminum chloride groups, a patient may not show any laboratory abnormalities either.…”

“…Our laboratory, as well as others, has previously shown that hepatocyte growth factor may be protective of PNALD, although this was in a different model. 10,16,17 One of the first steps in studying any disease process is a reproducible animal model. We believe that we have developed a rat model of PNALD using daily injections of aluminum chloride.…”

Hepatocyte growth factor and omega-3–enriched feeds have a synergistic effect on mucosal mass in an animal model of inflammatory bowel disease

“…Our laboratory has evaluated its use in the treatment of short bowel syndrome [20], parenteral nutrition-associated liver disease [21], and IBD [1,2]. Specifically, for the treatment of IBD in a rat model, we found that HGF ameliorates the diarrhea and gross inflammation.…”